Type 2 Diabetes

>

Latest News

Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD | Image Credit: Mount Sinai
Sotagliflozin Cuts MACE Risk By 23% in Patients with Type 2 Diabetes, CKD

February 18th 2025

Dual SGLT1/2 inhibition with sotagliflozin significantly reduced both heart attacks and stroke in a prespecified secondary analysis of the SCORED trial.

FDA
FDA Approves Merilog, Biosimilar Product of Insulin Aspart (Novolog) for Diabetes

February 14th 2025

CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes | Image Credit: LinkedIn
CELZ-201 Cuts Insulin Dependency at 1 Year in Patients with Type 2 Diabetes

February 11th 2025

Novo Nordisk | Credit: Novo Nordisk
Monlunabant Misses Primary Endpoint in Phase 2 Diabetic Kidney Disease Trial

February 5th 2025

Kasia Lipska, MD, MHS, associate professor of medicine
Investigating the Link Between Type 2 Diabetes and Infection

February 4th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.